Skip to main content
. 2018 Feb 1;2018(2):CD004879. doi: 10.1002/14651858.CD004879.pub5

cb Nicholls 2004.

Methods Retrospective cohort study of an outbreak of influenza A(H3N2) between 10 March and 5 April 2002 in a semi‐closed, highly vaccinated religious community in the UK. 90% of members of the community had been vaccinated before 7 November 2001. Data collected by self completion questionnaire, response rate was 92% (350/380).
Participants 350 residents of religious community including 133 children aged 0 to 14 years
Interventions Inactivated trivalent influenza vaccine containing A/Moscow/10/99‐like (H3N2), A/New Caledonia/20/99‐like (H1N1), and B/Sichuan/379/99‐like. The study reports a comparison of efficacy of the vaccine in members vaccinated in the USA with those vaccinated in the UK, in effect testing the hypothesis of possible lower efficacy of the UK‐administered vaccine.
Outcomes Serological
 Throat swabs from 39 case volunteers, 10 non‐cases, and 5 of undefined status. Paired sera from 9 members and single sera from 2 were drawn. 27 throat swabs were positive for H3N2/Panama/2007/99‐like, which is well matched to vaccine content.
Effectiveness
 A case was defined as self reported fever or chills accompanied by 1 or more of cough, sore throat, headache. Outcomes were evaluated by questionnaires distributed on 2 April 2002.
Safety
 N/A
Funding Source Unclear
Notes The authors conclude that the vaccine was not effective in preventing the outbreak, despite being well matched to the circulating virus (risk of developing ILI symptoms was not significantly different between vaccinated and UV: OR 1.14, 95% CI 0.41 to 3.14). VE was ‐5% in those vaccinated in the UK and 77% (53.2% to 88.4%) for those vaccinated elsewhere, mainly in the USA. The study reflects its mostly retrospective nature. The outbreak peaked on 20 March, 5 days before the arrival of the investigators. We do not understand why there is no matching of ILI cases with positive influenza diagnosis by vaccine exposure. Why report effectiveness when they could report efficacy?
Risk of bias
Bias Authors' judgement Support for judgement
PCS/RCS‐Selection Exposed cohort High risk Selected cohort
PCS/RCS‐Selection Non Exposed cohort Unclear risk Same community
PCS/RCS‐Comparability High risk Insufficient information
PCS/RCS‐Assessment of Oucome High risk Self report
Summary assessments High risk Plausible bias that seriously weakens confidence in the results